Driven by rising disease awareness and a growing cohort of patients who fail to respond to traditional antihistamines, the therapeutic landscape for chronic spontaneous urticaria is undergoing a major shift. The recent FDA approval of dupilumab for younger pediatric populations has signaled a transition toward more specialized, targeted interventions. With the market expected to grow through 2036, pharmaceutical developers are racing to introduce advanced alternatives to conventional biologics.

Key players including Celldex Therapeutics, Sanofi, and Jasper Therapeutics are advancing promising candidates through clinical development. Notable pipeline assets such as barzolvolimab, rilzabrutinib, and briquilimab aim to address the limitations of current management strategies by targeting specific signaling pathways like KIT and BTK. These oral small molecules and monoclonal antibodies represent a strategic pivot toward enhancing patient convenience and achieving sustained disease remission, marking a significant evolution from legacy treatment protocols.